EMEA-000527-PIP01-08

Invented name	Lucentis
Active substance	ranibizumab
Therapeutic area	Ophthalmology
Decision number	P/183/2009
PIP number	EMEA-000527-PIP01-08
Pharmaceutical form(s)	Solution for injection – single-use vial Solution for injection – single-use pre-filled syringe
Condition(s) / indication(s)	Visual impairment due to macular edema associated with branch retinal vein occlusion Visual impairment due to macular edema associated with central retinal vein occlusion Visual impairment due to diabetic macular edema
Route(s) of administration	Intravitreal use
Contact for public enquiries	Novartis Europharm Limited E-mail: paediatric.enquiries@novartis.com Phone: +41 61 324 1111
Decision type	W: decision granting a waiver in all age groups for all conditions or indications

Add your rating

★ ★ ★ ★ ★